Open Access. Powered by Scholars. Published by Universities.®
Cell and Developmental Biology
Hematology/Oncology and Stem Cell Therapy
Clinical research; Poor-risk AML; Post-HSCT low dose azacitidine; Post-transplantation maintenance; Stem cell transplantation
Articles 1 - 1 of 1
Full-Text Articles in Life Sciences
Azacitidine Maintenance Therapy Postallogeneic Stem Cell Transplantation In Poorrisk Acute Myeloid Leukemia, Amany R. Keruakous, Jennifer Holter-Chakrabarty, Sarah A. Schmidt, Mohamad O. Khawandanah, George Selby, Carrie Yuen
Azacitidine Maintenance Therapy Postallogeneic Stem Cell Transplantation In Poorrisk Acute Myeloid Leukemia, Amany R. Keruakous, Jennifer Holter-Chakrabarty, Sarah A. Schmidt, Mohamad O. Khawandanah, George Selby, Carrie Yuen
Hematology/Oncology and Stem Cell Therapy
Objective/Background: Allogeneic hematopoietic stem cell transplant (HSCT) is the potential curative modality for poor-risk acute myeloid leukemia (AML), relapse remains the main reason for transplant failure. Early-phase studies showed azacitidine is safe for post-transplant maintenance therapy in AML. Methods: We performed a single institutional prospective cohort study to evaluate the benefit of azacitidine maintenance therapy following allogeneic HSCT in poor-risk AML. The main objective of this study is to generate a hypothesis aiming to optimize post-transplantation outcomes in poor-risk AML. Forty-nine adults with poor-risk AML who underwent allogeneic HSCT were evaluated in a nonrandomized prospective cohort fashion. Thirty-one participants received …